10x Genomics (TXG) Total Non-Current Liabilities (2018 - 2026)

10x Genomics' Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $200.2 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 4.77% year-over-year to $200.2 million; the TTM figure through Mar 2026 stood at $200.2 million (up 4.77% YoY), while the FY2025 annual figure was $243.8 million, up 19.82% from the prior year.
• Total Non-Current Liabilities came in at $200.2 million for Q1 2026 at 10x Genomics, down from $243.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $243.8 million in Q4 2025 to a low of $188.0 million in Q1 2022.
• A 5-year average of $207.3 million and a median of $203.5 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities slipped 10.02% in 2023 and climbed 19.82% in 2025, its largest moves.
• 10x Genomics' Total Non-Current Liabilities stood at $220.3 million in 2022, then dropped by 0.2% to $219.8 million in 2023, then dropped by 7.44% to $203.5 million in 2024, then advanced by 19.82% to $243.8 million in 2025, then retreated by 17.88% to $200.2 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $200.2 million, $243.8 million, and $235.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison